Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow CITIUS ONCOLOGY, INC.

Get SEC filing alerts via email and in your feed for CITIUS ONCOLOGY, INC.

CTOR

CITIUS ONCOLOGY, INC.

About CITIUS ONCOLOGY, INC.

Citius Oncology develops targeted cancer therapies, focusing on innovative formulations with reduced development risks. Its lead product, LYMPHIR, treats cutaneous T-cell lymphoma (CTCL), serving an underserved market exceeding $400 million. The company advances its products through licensing, clinical trials, and strategic partnerships, aiming for commercialization in the U.S. and global markets, supported by intellectual property, regulatory approvals, and third-party manufacturing.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from CITIUS ONCOLOGY, INC.

1
1
CITIUS ONCOLOGY, INC. Citius Oncology Reports $1.67 Million Revenue in Q2 2026, Faces $26.61 Million Net Loss

Via official filing (AI summary) | 19 days ago | 0 comments

2
1
CITIUS ONCOLOGY, INC. Citius Oncology Reports First Revenue of $3.94 Million Following LYMPHIR Launch

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
CITIUS ONCOLOGY, INC. Citius Oncology Reports $24.8 Million Net Loss and No Revenue in Annual Filing

Via official filing (AI summary) | 5 months ago | 0 comments

4
1
CITIUS ONCOLOGY, INC. Citius Oncology Reports Increased Net Loss and Prepares for LYMPHIR Launch

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
CITIUS ONCOLOGY, INC. Citius Oncology Reports Increased Net Loss and Financial Challenges in Q2 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
CITIUS ONCOLOGY, INC. Citius Oncology Reports $6.66 Million Net Loss, Faces Liquidity Challenges

Via official filing (AI summary) | over 1 year ago | 0 comments